Clincosm LogoSign in Get a demo

Efficacy of Lianhua Qingwen in Treating Patients Infected With the Omicron Variant of the COVID-19

Sponsor
Qianfoshan Hospital (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05778318
Collaborator
(none)
200
Enrollment
15.4
Anticipated Duration (Months)

Study Details

Study Description

Brief Summary

A retrospective analysis was conducted on patients infected with the Omicron variant of COVID-19 diagnosed from August 2022 to now. Patients were divided into observation groups and control groups according to whether or not oral Lianhua Qingwen granules were used. Through data analysis and follow-up, the effectiveness of Lianhua Qingwen in treating patients infected with the Omicron variant of COVID-19 was discussed.

Condition or Disease Intervention/Treatment Phase
  • Drug: The group of patients who received Lianhua Qingwen orally
  • Other: The group of patients who did not receive Lianhua Qingwen orally

Study Design

Study Type:
Observational
Anticipated Enrollment :
200 participants
Observational Model:
Cohort
Time Perspective:
Retrospective
Official Title:
Efficacy of Lianhua Qingwen in Treating Patients Infected With the Omicron Variant of the COVID-19
Anticipated Study Start Date :
Mar 20, 2023
Anticipated Primary Completion Date :
Apr 30, 2024
Anticipated Study Completion Date :
Jun 30, 2024

Arms and Interventions

Arm Intervention/Treatment
Control group

Patients without Lianhua Qingwen treatment.

Other: The group of patients who did not receive Lianhua Qingwen orally
The group of patients who did not receive Lianhua Qingwen orally.
Observation Group

Patients with Lianhua Qingwen treatment.

Drug: The group of patients who received Lianhua Qingwen orally
Lianhua Qingwen Granules: oral. One bag at a time, three times a day. The course of treatment for mild and ordinary cases of novel coronavirus pneumonia is 7-10 days.

Outcome Measures

Primary Outcome Measures

  1. Disappearance rate of symptoms [two weeks]

    Disappearance rate of symptoms (fever, fatigue, cough)

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 80 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:

  • For patients infected with the Omicron variant, the diagnostic criteria are confirmed cases of COVID-19 and clinical classification according to the diagnostic criteria of Prevention and Control Protocol for COVID-19 (Trial Eighth Edition) issued by the National Health and Construction Commission.

  • The clinical symptoms were classified as mild or ordinary.

  • They have been vaccinated against the COVID-19.

Exclusion Criteria:

  • Patients receiving antiviral or antibiotic drugs

  • Severe and critical patients with COVID-19.

  • Patients with chronic respiratory diseases, bacterial infections of the respiratory system, and other respiratory diseases affecting the study.

  • Patients with serious primary diseases of the heart, brain, lung, liver, kidney, and hematopoietic systems, as well as mental diseases.

  • Allergic reaction to Lianhua Qingwen granules.

  • Excluded patients treated with the same drug as Lianhua Qingwen.

Contacts and Locations

Locations

No locations specified.

Sponsors and Collaborators

  • Qianfoshan Hospital

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Qian Qi, Dr., Qianfoshan Hospital
ClinicalTrials.gov Identifier:
NCT05778318
Other Study ID Numbers:
  • YXLL-KY-2022(095)
First Posted:
Mar 21, 2023
Last Update Posted:
Mar 21, 2023
Last Verified:
Mar 1, 2023
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:
COVID-19

Study Results

No Results Posted as of Mar 21, 2023